Press Release: Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Dow Jones
02-06

Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

PR Newswire

BOSTON, Feb. 6, 2025

Financial release accessible online

BOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation $(HAE)$ announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 6, 2025. The conference call and webcast can be accessed with the following information:

   -- Teleconference 
      link: https://register.vevent.com/register/BIda08929a4d56464eb33eccb945ef 
      985e 
 
   -- Once registration is completed, participants will receive a dial-in 
      number along with a personalized PIN to access the call. While not 
      required, it is recommended that participants join 10 minutes prior to 
      the event start. 
 
   -- A live webcast of the call can be accessed on Haemonetics' investor 
      relations website or via the following link: 
      https://edge.media-server.com/mmc/p/63jte4ra 

In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.

Direct link to 3Q FY25 Earnings Release:

https://haemonetics.gcs-web.com/static-files/36134646-a371-4076-87b9-26673f9f10f3

A replay of the conference call and webcast will be available for one year beginning on February 6, 2025, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

 
Investor Contacts: 
Olga Guyette, Vice President-Investor   David Trenk, Manager-Investor 
Relations & Treasury                    Relations 
(781) 356-9763                          (203) 733-4987 
olga.guyette@haemonetics.com            david.trenk@haemonetics.com 
 
Media Contact: 
Josh Gitelson, Sr. Director-Global 
Communications 
(781) 356-9776 
josh.gitelson@haemonetics.com 
 

View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-3rd-quarter-fiscal-year-2025-earnings-release-available-on-investor-relations-website-302368961.html

SOURCE Haemonetics Corporation

 

(END) Dow Jones Newswires

February 06, 2025 06:00 ET (11:00 GMT)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10